HRCM
BPMC

Hood River Capital Management’s Blueprint Medicines BPMC Stock Holding History

Hood River Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-900,205
Closed -$79.7M – 151
2025
Q1 		$79.7M Buy
900,205
+20,273
+2% +$1.98M 1.36% 21
2024
Q4 		$76.7M Buy
879,932
+207,496
+31% +$19M 1.13% 31
2024
Q3 		$62.2M Buy
672,436
+169,616
+34% +$16.8M 1% 36
2024
Q2 		$54.2M Buy
502,820
+32,694
+7% +$3.27M 1.12% 28
2024
Q1 		$44.6M Buy
470,126
+30,108
+7% +$2.58M 0.99% 35
2023
Q4 		$40.6M Buy
440,018
+166,105
+61% +$10.8M 1.12% 36
2023
Q3 		$13.8M Buy
273,913
+464
+0.2% +$24.8K 0.44% 77
2023
Q2 		$17.3M Buy
+273,449
New +$14.9M 0.51% 67

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hood River Capital Management's BPMC Position: Q2 2025 in Review

Hood River Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 900,205 shares — an estimated $79.7M sold.

Hood River Capital Management first reported a position in BPMC in Q2 2023 and held it in 8 quarters. The position peaked at $79.7M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Hood River Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Hood River Capital Management sold 900,205 Blueprint Medicines shares in Q2 2025, an estimated $79.7M.
  • Hood River Capital Management first reported a position in Blueprint Medicines in Q2 2023 and held it in 8 quarters.
  • Hood River Capital Management's Blueprint Medicines position peaked at $79.7M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Hood River Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.